-
Home in Nigeria, ex-refugees find themselves in a war zone
-
Doncic's Lakers hold off Wembanyama's Spurs, Blazers silence Thunder
-
For Turkey's LGBTQ community, draft law sparks existential alarm
-
Musk's $1 trillion pay package to face Tesla shareholder vote
-
Tonga rugby league star out of intensive care after seizure
-
Argentine ex-president Kirchner goes on trial in new corruption case
-
Dams, housing, pensions: Franco disinformation flourishes online
-
Endo returns as Japan look to build on Brazil win
-
Franco captivates young Spaniards 50 years after death
-
German steel industry girds for uncertain future
-
IPL champions Bengaluru could be sold for 'as much as $2 billion'
-
Budget impasse threatens Belgium's ruling coalition
-
New Zealand ex-top cop admits to having material showing child abuse, bestiality
-
BoE set for finely balanced pre-budget rate call
-
Australian kingpin obtains shorter sentence over drug charge
-
Weatherald's unenviable Ashes task: fill giant hole at top left by Warner
-
Ovechkin first to score 900 NHL goals as Capitals beat Blues
-
On Mexico City's streets, vendors fight to make it to World Cup
-
Asian markets bounce from selloff as US jobs beat forecasts
-
Philippine death toll tops 140 as typhoon heads towards Vietnam
-
Kyrgios targets 'miracle' Australian Open return after knee improves
-
'AI president': Trump deepfakes glorify himself, trash rivals
-
Belgium probes drone sightings after flights halted overnight
-
Five things to know about 'forest COP' host city Belem
-
World leaders to rally climate fight ahead of Amazon summit
-
Engine fell off US cargo plane before deadly crash: officials
-
Mexican leader calls for tougher sexual harassment laws after attack
-
Meghan Markle set for big screen return: reports
-
Japan deploys troops after wave of deadly bear attacks
-
FIFA announce new peace prize to be awarded at World Cup draw in Washington
-
Australia's Cummins hints at return for second Ashes Test
-
Boeing settles with one plaintiff in 737 MAX crash trial
-
Man City win as Inter stay perfect, Barca held in Champions League
-
French superstar DJ Snake wants new album to 'build bridges'
-
Barca rescue draw at Club Brugge in six-goal thriller
-
Foden hits top form as Man City thrash Dortmund
-
NBA officials brief Congress committee over gambling probe
-
Inter beat Kairat Almaty to maintain Champions League perfection
-
Newcastle sink Bilbao to extend Champions League winning run
-
Wall Street stocks rebound after positive jobs data
-
LPGA, European tour partner with Saudis for new Vegas event
-
Eyes turn to space to feed power-hungry data centers
-
Jazz lose Kessler for season with shoulder injury
-
League scoring leader Messi among MLS Best XI squad
-
MLS bans Suarez for Miami's winner-take-all playoff match
-
McIlroy appreciates PGA of America apology for Ryder Cup abuse
-
Garnacho equaliser saves Chelsea in Qarabag draw
-
Promotions lift McDonald's sales in tricky consumer market
-
Five things to know about New York's new mayor
-
Anisimova beats Swiatek to reach WTA Finals last four
More Ebola trial vaccines arrive in Uganda
Uganda announced Thursday that it had received shipments of two more trial vaccines to test against a strain of Ebola responsible for dozens of deaths in the East African nation.
Since authorities declared an Ebola outbreak on September 20, Uganda has registered 142 confirmed cases and 56 deaths, but the spread has slowed in recent weeks, sparking hope that the epidemic could be on its way out.
The outbreak has been caused by the so-called Sudan strain of the virus, for which there is currently no vaccine.
But three candidate vaccines -- one developed by Oxford University and the Jenner Institute in Britain, another from the Sabin Vaccine Institute in the United States, and a third from the International AIDS Vaccine Initiative (IAVI) -- will be trialed in Uganda in the coming weeks.
On December 8, Uganda received its first shipment of doses from the Sabin Vaccine Institute.
"On Saturday December 17, we received two more candidate vaccines from Merck/IAVI of 2,160 doses and 2,000 doses from Oxford University/Jenner Institute manufactured by the Serum Institute of India," Health Minister Jane Ruth Aceng told a press briefing on Thursday.
They will be used in a so-called ring vaccination trial, where all contacts of confirmed Ebola patients, and contacts of contacts, are jabbed along with frontline and health workers.
Ugandan authorities said last month that new cases were falling, and the last confirmed patient with the disease was discharged from hospital on November 30.
The absence of active Ebola cases in recent days has held up the vaccine trials, according to international health experts working in Uganda.
Aceng said however that the authorities had already begun enlisting volunteers for the trials, adding that Uganda would take part in a global expert consultation meeting on Ebola on January 12.
The government last week lifted a two-month lockdown on two Ebola hotspots, removing curbs including a dusk-to-dawn curfew, a ban on personal travel and the closure of markets, bars and churches.
According to the World Health Organization (WHO), an outbreak of the disease ends when there are no new cases for 42 consecutive days -- twice the incubation period of Ebola.
Ebola spreads through bodily fluids. Common symptoms are fever, vomiting, bleeding and diarrhoea.
Outbreaks are difficult to contain, especially in urban environments.
A.AlHaj--SF-PST